Sutro Biopharma: Pay

Sutro Biopharma paid its 4 named executives $5.0M in total in FY2025 (Dec). CEO Jane Chung, R.Ph. was paid $1.6M of that.

Pay$100 in the stock at the end of FY22 → $14
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

William J. NewellFormer Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Jane Chung, R.Ph.Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Hans-Peter Gerber, Ph.D.Chief Scientific Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Gregory ChowChief Financial Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $5.6M. CEO pay of Sutro Biopharma for that year is not on file.

  1. 1Arcus Biosciences
  2. 2Zymeworks
  3. 3Nurix Therapeutics
  4. 4Kura Oncology
  5. 5Replimune Group
  6. 6Gossamer Bio
  7. 7Sutro BiopharmaNot disclosed
  8. 8AlectorNot disclosed
  9. 9Allogene TherapeuticsNot disclosed
  10. 10Anaptys Bio, Inc.Not disclosed
  11. 11Atara Biotherapeutics, Inc.Not disclosed
  12. 12Caribou BiosciencesNot disclosed
  13. 13G1 Therapeutics, Inc.Not disclosed
  14. 14Gritstone Bio, Inc.Not disclosed
  15. 15IGM Biosciences, Inc.Not disclosed
  16. 16MacrogenicsNot disclosed
  17. 17Mersana Therapeutics, Inc.Not disclosed
  18. 18Poseida Therapeutics, Inc.Not disclosed
  19. 19Sangamo Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.